SCHEMBL656219

SCHEMBL656219

O=C(/C=C/c1ccc2ccccc2c1)c1ccccc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 6/20 0.77
PTPN1 P18031 1/20 0.77
CYP1B1 Q16678 3/20 0.71
CYP1A2 P05177 2/20 0.71
CYP1A1 P04798 1/20 0.71
CYP2D6 P10635 1/20 0.71
MAOB P27338 3/20 0.69
MAOA P21397 1/20 0.69
RAB9A P51151 2/20 0.68
KMT2A Q03164 2/20 0.68
MEN1 O00255 1/20 0.68
NPC1 O15118 1/20 0.68
CYP2C19 P33261 1/20 0.68
MAPT P10636 2/20 0.65
PLIN1 O60240 1/20 0.65
LMNA P02545 1/20 0.65
BCHE P06276 1/20 0.65
TNFRSF1A P19438 1/20 0.65
ACHE P22303 1/20 0.65
RECQL P46063 1/20 0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL656220 1.00 CYP3A4 (0.77) CYP3A4PTPN1CYP1B1CYP1A2CYP1A1
SCHEMBL29624424 1.00 CYP3A4 (0.77) CYP3A4PTPN1CYP1B1CYP1A2CYP1A1
SCHEMBL13680427 0.96 CYP3A4 (0.75) CYP3A4PTPN1CYP1B1CYP1A2CYP1A1
SCHEMBL6913489 0.91 CYP3A4 (0.74) CYP3A4PTPN1CYP1B1CYP1A2CYP1A1
SCHEMBL656428 0.90 CYP1B1 (0.81) CYP3A4PTPN1CYP1B1CYP1A2CYP1A1
SCHEMBL656427 0.90 CYP1B1 (0.81) CYP3A4PTPN1CYP1B1CYP1A2CYP1A1
SCHEMBL25221764 0.89 CYP3A4 (0.76) CYP3A4PTPN1CYP1B1CYP1A2CYP1A1
SCHEMBL15507014 0.89 CYP3A4 (0.76) CYP3A4PTPN1CYP1B1CYP1A2CYP1A1
SCHEMBL12158657 0.89 CYP3A4 (0.62) CYP3A4PTPN1CYP1B1CYP1A2CYP1A1
SCHEMBL11817525 0.87 CYP3A4 (0.74) CYP3A4PTPN1CYP1B1CYP1A2CYP1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116891496-A Preparation method and application of beta-chiral boron compound 湖北工程学院 2023-10-17 CN disclosed
EP-3749657-A1 A PROCESS FOR THE PREPARATION OF PYRYLIUM SALTS Council of Scientific & Industrial Research (IN) 2020-12-16 EP disclosed
CN-110204474-B Method for synthesizing tetra-substituted NH-pyrrole compound 浙江工业大学 2020-10-30 CN disclosed
CN-105732588-B Organic compound, light-emitting element, and light-emitting device 株式会社半导体能源研究所 2020-10-09 CN disclosed
WO-2019155485-A1 A PROCESS FOR THE PREPARATION OF PYRYLIUM SALTS COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2019-08-15 WO disclosed
US-10280156-B2 Heteroaromatic chalcone derivatives and their medical use MEDIZINISCHE UNIVERSITÄT WIEN (AT) 2019-05-07 US disclosed
US-9929352-B2 Organic compound, light-emitting element, display module, lighting module, light-emitting device, display device, electronic device, and lighting device SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2018-03-27 US disclosed
US-9929352-B2 Organic compound, light-emitting element, display module, lighting module, light-emitting device, display device, electronic device, and lighting device SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2018-03-27 US disclosed
US-9929352-B2 Organic compound, light-emitting element, display module, lighting module, light-emitting device, display device, electronic device, and lighting device SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2018-03-27 US disclosed
US-20170253583-A1 HETEROAROMATIC CHALCONE DERIVATIVES AND THEIR MEDICAL USE Universität Wien (AT) 2017-09-07 US disclosed
US-8304581-B2 Method of enantioselective addition to enones NATIONAL TSING HUA UNIVERSITY (TW) 2012-11-06 US disclosed
US-20120046307-A1 ALLOSTERIC PROTEIN KINASE MODULATORS UNIVERSITAET DES SAARLANDES (DE) 2012-02-23 US disclosed
US-20110282101-A1 METHOD OF ENANTIOSELECTIVE ADDITION TO ENONES NATIONAL TSING HUA UNIVERSITY (TW) 2011-11-17 US disclosed
US-20110282101-A1 METHOD OF ENANTIOSELECTIVE ADDITION TO ENONES NATIONAL TSING HUA UNIVERSITY (TW) 2011-11-17 US disclosed
EP-2349999-A1 ALLOSTERIC PROTEIN KINASE MODULATORS Universität des Saarlandes (DE) 2011-08-03 EP disclosed
US-7872029-B2 Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states BOWEN J PHILLIP 2011-01-18 US disclosed
WO-2010043711-A1 ALLOSTERIC PROTEIN KINASE MODULATORS UNIVERSITAET DES SAARLANDES (DE) 2010-04-22 WO disclosed
EP-2177510-A1 Allosteric protein kinase modulators Universität des Saarlandes (DE) 2010-04-21 EP disclosed
US-20090018167-A1 Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states Robinson, Thomas Philip (US) 2009-01-15 US disclosed
US-7432303-B2 Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states Bowen, J. Phillip (US) 2008-10-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090018167-A1 Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states FLT1, FLT4, VEGFA CYP3A4 1236/4885PTPN1 837/4885CYP1B1 747/4885
US-20170253583-A1 HETEROAROMATIC CHALCONE DERIVATIVES AND THEIR MEDICAL USE CYP2E1, CYP3A43, CYP11B1 CYP3A4 33/4885PTPN1 670/4885CYP1B1 25/4885
US-20120046307-A1 ALLOSTERIC PROTEIN KINASE MODULATORS AURKC, AURKA, AURKB CYP3A4 4232/4885PTPN1 1145/4885CYP1B1 4714/4885
US-20110282101-A1 METHOD OF ENANTIOSELECTIVE ADDITION TO ENONES CPNE4, ENY2, CYP3A4 CYP3A4 3/4885PTPN1 3693/4885CYP1B1 153/4885
US-10280156-B2 Heteroaromatic chalcone derivatives and their medical use CYP2E1, CYP3A43, CYP11B1 CYP3A4 33/4885PTPN1 670/4885CYP1B1 25/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.